B
Bernard Fisher
Researcher at University of Pittsburgh
Publications - 379
Citations - 70162
Bernard Fisher is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 108, co-authored 377 publications receiving 67479 citations. Previous affiliations of Bernard Fisher include University of Texas Health Science Center at San Antonio & Mercy Medical Center (Baltimore, Maryland).
Papers
More filters
Journal ArticleDOI
The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06.
Melvin Deutsch,Stephanie R. Land,Mirsada Begovic,H. Samuel Wieand,Norman Wolmark,Bernard Fisher +5 more
TL;DR: In the current study, the authors compared the incidence of subsequent primary lung carcinoma in patients with breast carcinoma who received radiotherapy as part of their treatment and in those patients who did not.
Journal ArticleDOI
Prognostic significance of eosinophils and mast cells in rectal cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01)
Edwin R. Fisher,Soonmyung Paik,Howard E. Rockette,Judith Jones,Richard Caplan,Bernard Fisher +5 more
TL;DR: It is concluded that numbers of eosinophils and mast cells may play a role in the natural history of rectal cancer but only the latter represents a prognostic parameter independent of Dukes' stage or nodal status.
Journal ArticleDOI
Long-term tamoxifen citrate use and potential ocular toxicity
Michael B. Gorin,Richard O. Day,Joseph P. Costantino,Bernard Fisher,Carol K. Redmond,Lawrence Wickerham,J. E. S. Gomolin,Richard G. Margolese,Mathen K. Mathen,David M. Bowman,David Kaufmann,Nikolay V. Dimitrov,Lawrence J. Singerman,Richard Bornstein,Norman Wolmark +14 more
TL;DR: Women with breast cancer currently taking part in a randomized clinical trial to determine the efficacy of tamoxifen (20 mg/day) in preventing recurrences should have a thorough baseline ophthalmic evaluation within the first year of initiating tamoxIFen therapy and receive appropriate follow-up evaluations.
Journal ArticleDOI
Studies concerning the regional lymph node in cancer. I. Initiation of immunity.
Bernard Fisher,Edwin R. Fisher +1 more
TL;DR: It is indicated that the regional lymph node is more important in the development of tumor immunity than in production of transplantation or hypersensitivity response and the role of the bloodstream in host sensitization to tumor.
Journal ArticleDOI
Prolonging tamoxifen therapy for primary breast cancer: findings from the national surgical adjuvant breast and bowel project clinical trial
Bernard Fisher,Arleen F. Brown,Norman Wolmark,Carol K. Redmond,Wickerham Dl,James L. Wittliff,Nikolay V. Dimitrov,S Legault-Poisson,H Schipper,David Prager +9 more
TL;DR: The benefit of tamoxifen given to tamoxIFen-responsive patients in conjunction with melphalan and fluorouracil appears to be enhanced when the tamox ifen treatment is continued beyond cessation of treatment with these agents.